Intravenous immunoglobulin: properties, mode of action and practical use in dermatology.

Since they were first administered to patients with antibody deficiency disorders over 50 years ago, human intravenous immunoglobulin preparations have been used successfully to treat a rapidly increasing number of autoimmune and inflammatory disorders, among which are a series of cutaneous autoimmune and inflammatory diseases. These include dermatomyositis, Kawasaki's disease, a number of autoimmune bullous diseases, severe adverse drug reactions, and other autoimmune and/or allergic conditions, such as atopic dermatitis. Although only a minority of these indications (dermatomyositis, Kawasaki's disease) are officially registered or based on double-blind, placebo-controlled clinical studies, the observed efficacy and safety profile of currently available intravenous immunoglobulin sometimes makes this a treatment of choice for initiation of therapy or for replacement of more toxic alternatives, such as systemic immunosuppressive medications. The increasing use of intravenous immunoglobulin has been associated with further understanding of its mechanism(s) of action, clinical manipulation and associated side-effects, as well as the introduction of improved or new types of intravenous immunoglobulin. This paper reviews the current knowledge of the mode of action of intravenous immunoglobulin, its reported therapeutic effects in cutaneous disease, its mode of administration and safety profile, and compares the currently available intravenous immunoglobulin preparations.

[1]  L. French,et al.  Toxic epidermal necrolysis and intravenous immunoglobulin: a review. , 2006, Seminars in cutaneous medicine and surgery.

[2]  A. Scope,et al.  The role of IVIg treatment in severe pemphigus vulgaris , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  M. Dalakas The role of high-dose immune globulin intravenous in the treatment of dermatomyositis. , 2006, International immunopharmacology.

[4]  D. Hamrock,et al.  Adverse events associated with intravenous immunoglobulin therapy. , 2006, International immunopharmacology.

[5]  T. D. Martin IGIV: contents, properties, and methods of industrial production--evolving closer to a more physiologic product. , 2006, International immunopharmacology.

[6]  E. Gelfand Differences between IGIV products: impact on clinical outcome. , 2006, International immunopharmacology.

[7]  S. Jolles,et al.  Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema. , 2006, International immunopharmacology.

[8]  A. Ahmed,et al.  Use of intravenous immunoglobulin therapy in autoimmune blistering diseases. , 2006, International immunopharmacology.

[9]  Y. Daoud,et al.  Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. , 2006, International immunopharmacology.

[10]  J. Huggins,et al.  Use of intravenous immunoglobulin G (IVIG). , 2006, Best practice & research. Clinical haematology.

[11]  P. Lázaro,et al.  Epidermolysis bullosa acquisita: diagnosis by fluorescence overlay antigen mapping and clinical response to high‐dose intravenous immunoglobulin , 2006, Clinical and experimental dermatology.

[12]  Y. Shoenfeld,et al.  Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris , 2005, Clinical and experimental immunology.

[13]  G. Lauzon,et al.  Combination Oral Prednisone and Intravenous Immunoglobulin in the Treatment of Scleromyxedema , 2005, Journal of cutaneous medicine and surgery.

[14]  H. Chng,et al.  High‐Dose Intravenous Immunoglobulins in the Treatment of Toxic Epidermal Necrolysis: An Asian Series , 2005, The Journal of dermatology.

[15]  M. Pittelkow,et al.  Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. , 2005, Mayo Clinic proceedings.

[16]  Y. Shoenfeld,et al.  Intravenous immunoglobulin and the kidney--a two-edged sword. , 2004, Seminars in arthritis and rheumatism.

[17]  N. Al‐Mutairi,et al.  Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis , 2004, International journal of dermatology.

[18]  K. Wolff,et al.  Unusual clinical manifestation of linear IgA dermatosis: a report of two cases. , 2004, Journal of the American Academy of Dermatology.

[19]  F. Lawlor,et al.  Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin , 2004, Clinical and experimental dermatology.

[20]  R. Cartotto,et al.  Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. , 2004, The Journal of burn care & rehabilitation.

[21]  Moses Rodriguez,et al.  Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a , 2004, Multiple sclerosis.

[22]  H. Kurzen,et al.  Unusual spindle cell squamous carcinoma in a renal transplant patient. , 2004, Acta dermato-venereologica.

[23]  M. Richard,et al.  [Treatment of pemphigus with intravenous immunoglobulin]. , 2004, Annales de dermatologie et de venereologie.

[24]  R. Gamelli,et al.  Toxic epidermal necrolysis: does immunoglobulin make a difference? , 2004, The Journal of burn care & rehabilitation.

[25]  S. Kaveri,et al.  Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[26]  A. Eisen,et al.  Scleromyxoedema: treatment of cutaneous and systemic manifestations with high‐dose intravenous immunoglobulin , 2003, The British journal of dermatology.

[27]  H. Simon,et al.  Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. , 2003, The Journal of allergy and clinical immunology.

[28]  G. Dawn,et al.  Effect of high‐dose intravenous immunoglobulin in delayed pressure urticaria , 2003, The British journal of dermatology.

[29]  E. Bröcker,et al.  Successful treatment of linear IgA disease with salazosulphapyridine and intravenous immunoglobulins , 2003, The British journal of dermatology.

[30]  M. Cartwright,et al.  The clinical features of 16 cases of stroke associated with administration of IVIg , 2003, Neurology.

[31]  E. Bröcker,et al.  Lack of response of elephantiasic pretibial myxoedema to treatment with high‐dose intravenous immunoglobulins , 2003, Clinical and experimental dermatology.

[32]  R. Parslew,et al.  Superficial granulomatous pyoderma treated with intravenous immunoglobulin. , 2003, Journal of the American Academy of Dermatology.

[33]  S. Kaveri,et al.  Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. , 2003, Blood.

[34]  B. Seitz,et al.  Annular Crystalline Keratopathy in Association With Immunoglobulin Therapy for Pyoderma Gangrenosum , 2003, Cornea.

[35]  S. Jolles,et al.  Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. , 2003, Acta dermato-venereologica.

[36]  A. Costanzo,et al.  High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. , 2003, Acta dermato-venereologica.

[37]  R. Kirsner,et al.  Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. , 2003, Archives of dermatology.

[38]  J. Roujeau,et al.  Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. , 2003, Archives of dermatology.

[39]  R. S. Padilla,et al.  Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. , 2003, Archives of dermatology.

[40]  A. Ahmed,et al.  Epidermolysis bullosa acquisita and multiple myeloma. , 2002, Journal of the American Academy of Dermatology.

[41]  A. Sreih,et al.  Thrombotic Complications After Intravenous Immunoglobulin Therapy in Two Patients , 2002, Pharmacotherapy.

[42]  A. Ahmed,et al.  Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long‐term follow‐up: influence of treatment on antibody titres to human α6 integrin , 2002, Clinical and experimental immunology.

[43]  S. Chevret,et al.  A randomized controlled evaluator‐blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis , 2002, The British journal of dermatology.

[44]  E. Ruocco,et al.  Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. , 2002, Archives of dermatology.

[45]  A. Ahmed,et al.  Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. , 2002, European journal of dermatology : EJD.

[46]  E. Rallis,et al.  Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulins , 2002, Journal of the European Academy of Dermatology and Venereology : JEADV.

[47]  A. Doria,et al.  Intravenous immunoglobulins control scleromyxoedema , 2002, Annals of the rheumatic diseases.

[48]  T. B.,et al.  Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin. , 2002 .

[49]  K. Bhol,et al.  Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. , 2002, Clinical immunology.

[50]  A. Ahmed,et al.  Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. , 2002, Journal of the American Academy of Dermatology.

[51]  A. Ahmed,et al.  Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. , 2001, Journal of the American Academy of Dermatology.

[52]  A. Bridges,et al.  Intravenous immune globulin: fighting antibodies with antibodies. , 2001, Journal of the American Academy of Dermatology.

[53]  A. Ahmed,et al.  Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. , 2001, Journal of the American Academy of Dermatology.

[54]  K. Bhol,et al.  Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long‐term follow‐up and treatment responses , 2001, Clinical and experimental immunology.

[55]  A. Ahmed,et al.  Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy. , 2001, Archives of dermatology.

[56]  J. Ravetch,et al.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. , 2001, Science.

[57]  S. Chimenti,et al.  The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum , 2001, The Journal of dermatological treatment.

[58]  R. Asero Are IVIG for chronic unremitting urticaria effective? , 2000, Allergy.

[59]  C. Foster,et al.  Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy. , 2000, Ophthalmology.

[60]  I. Forgacs,et al.  Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). , 2000, Journal of the American Academy of Dermatology.

[61]  W. Stolz,et al.  The effectiveness of low-dose intravenous immunoglobulin in chronic urticaria. , 2000, Acta dermato-venereologica.

[62]  B. Bonnekoh,et al.  Epidermolysis bullosa acquisita with ultraviolet radiationsensitivity , 2000, The British journal of dermatology.

[63]  S. Jolles,et al.  The treatment of atopic dermatitis with adjunctive high‐dose intravenous immunoglobulin: a report of three patients and review of the literature , 2000, The British journal of dermatology.

[64]  W. Stolz,et al.  High‐dose intravenous immune globulin is also effective in linear IgA disease , 2000, The British journal of dermatology.

[65]  M. Kuo,et al.  Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[66]  R. Stadler,et al.  Posttraumatisches Pyoderma gangraenosum: Kombinationstherapie mit intravenösen Immunglobulinen und systemischen Kortikosteroiden , 1999, Der Hautarzt.

[67]  A. Ahmed,et al.  Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. , 1999, Ophthalmology.

[68]  M. Sturzenegger,et al.  Adverse Effects of Intravenous Immunoglobulin Therapy , 1999, Drug safety.

[69]  M. Jonkman,et al.  Successful treatment of recalcitrant penicillamine‐induced pemphigus foliaceus by low‐dose intravenous immunoglobulins , 1999, The British journal of dermatology.

[70]  K. Harman,et al.  High‐dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases , 1999, The British journal of dermatology.

[71]  E. Gelfand,et al.  Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. , 1999, The Journal of allergy and clinical immunology.

[72]  A. Ahmed,et al.  Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy. , 1999, Journal of the American Academy of Dermatology.

[73]  P. Altmeyer,et al.  Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin. , 1998, Journal of the American Academy of Dermatology.

[74]  J. Tschopp,et al.  Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. , 1998, Science.

[75]  S. Kaveri,et al.  Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. , 1998, Journal of immunology.

[76]  David B. Speights,et al.  High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[77]  Winkelmann,et al.  Intravenous immunoglobulin in autoimmune chronic urticaria , 1998, The British journal of dermatology.

[78]  S. Whittaker,et al.  Dermatological uses of high-dose intravenous immunoglobulin. , 1998, Archives of dermatology.

[79]  W. Douglas,et al.  Cicatricial pemphigoid treated with intravenous immunoglobulin , 1997, The British journal of dermatology.

[80]  H. Boldt,et al.  Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. , 1997, American journal of ophthalmology.

[81]  G. Schuler,et al.  Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. , 1997, Journal of the American Academy of Dermatology.

[82]  U. Andersson,et al.  Intravenous immune globulin affects cytokine production in T lymphocytes and monocytesjmacrophages , 1996, Clinical and experimental immunology.

[83]  E. Gelfand,et al.  Intravenous immune globulin: an alternative therapy in steroid‐dependent allergic diseases , 1996, Clinical and experimental immunology.

[84]  B. Vermeer,et al.  Adjuvant high‐dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients , 1995, The British journal of dermatology.

[85]  C. Saadeh,et al.  Dermatomyositis: remission induced with combined oral cyclosporine and high-dose intravenous immune globulin. , 1995, Southern medical journal.

[86]  C. Sunderkötter,et al.  Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins , 1995, The British journal of dermatology.

[87]  V. Dubowitz,et al.  Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases. , 1995, Archives of disease in childhood.

[88]  N. Shear,et al.  Efficacy of human intravenous immune globulin in pyoderma gangrenosum. , 1995, Journal of the American Academy of Dermatology.

[89]  M. Dalakas,et al.  High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. , 1994, The Journal of clinical investigation.

[90]  M. Dalakas,et al.  Aseptic Meningitis Associated with High-Dose Intravenous Immunoglobulin Therapy: Frequency and Risk Factors , 1994, Annals of Internal Medicine.

[91]  B. Wechsler,et al.  Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. , 1994, The Journal of rheumatology.

[92]  H. Kimata High dose gammaglobulin treatment for atopic dermatitis. , 1994, Archives of disease in childhood.

[93]  S. Dalac,et al.  Juvenile dermatomyositis: treatment with intravenous gammaglobulin , 1994, The British journal of dermatology.

[94]  W. James,et al.  Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. , 1994, Journal of the American Academy of Dermatology.

[95]  A. Antonelli,et al.  Pretibial myxedema and high-dose intravenous immunoglobulin treatment. , 1994, Thyroid : official journal of the American Thyroid Association.

[96]  J. Dambrosia,et al.  A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. , 1993, The New England journal of medicine.

[97]  G. Rassner,et al.  Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. , 1993, Journal of the American Academy of Dermatology.

[98]  E. Silverman,et al.  Intravenous immunoglobulin therapy: magic or black magic. , 1992, The Journal of rheumatology. Supplement.

[99]  J. Dwyer Manipulating the immune system with immune globulin. , 1992, The New England journal of medicine.

[100]  E. Silverman,et al.  Treatment of dermatomyositis with intravenous gammaglobulin. , 1991, The American journal of medicine.

[101]  M. Frank,et al.  High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes , 1991 .

[102]  C. Bodemer,et al.  Efficacy of intravenous immunoglobulins in sclerodermatomyositis , 1990, The British journal of dermatology.

[103]  M. Yebra,et al.  Ciprofloxacin in a case of Q fever endocarditis. , 1990, The New England journal of medicine.

[104]  B. Wechsler,et al.  Intravenous immunoglobulin for polymyositis and dermatomyositis , 1990, The Lancet.

[105]  M. Casteels-van Daele,et al.  Intravenous immune globulin and acute aseptic meningitis. , 1990, The New England journal of medicine.

[106]  M. Frank,et al.  High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. , 1989, Blood.

[107]  J. Newburger,et al.  The treatment of Kawasaki syndrome with intravenous gamma globulin. , 1986 .

[108]  M. Kazatchkine,et al.  ANTI-IDIOTYPIC SUPPRESSION OF AUTOANTIBODIES TO FACTOR VIII (ANTIHAEMOPHILIC FACTOR) BY HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN , 1984, The Lancet.

[109]  D. Fisher,et al.  Pyoderma gangrenosum associated with hypogammaglobulinemia; report of two cases. , 1958, A.M.A. archives of dermatology.

[110]  P. V. Marcussen Hypogammaglobulinemia in pyoderma gangrenosum. , 1955, The Journal of investigative dermatology.